表纸
市场调查报告书

创伤后压力症候群(PTSD):开发平台分析

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 213134
出版日期 内容资讯 英文 142 Pages
订单完成后即时交付
价格
Back to Top
创伤后压力症候群(PTSD):开发平台分析 Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 142 Pages
简介

创伤后压力症候群(PTSD)是指遭遇或目击可怕的事情后引起的精神卫生状态。症状不仅有不断闪回事件画面、恶梦及严重不安,还包括了无法控制自己对创伤回亿的思考。治疗有给予抗忧鬱药,抗焦虑·意识疗法等。

本报告提供全球治疗创伤后压力症候群(PTSD)用之开发中产品的开发情形相关分析,提供您产品开发·上市的最新趋势,临床实验的各阶段产品一览,主要企业简介,主要药物概要,最新的产业趋势等资讯。

目录

简介

  • 分析范围

创伤后压力症候群(PTSD)概要

治疗药的开发

  • 创伤后压力症候群(PTSD)开发中产品:概要
  • 创伤后压力症候群(PTSD)开发中产品:比较分析

创伤后压力症候群(PTSD):各企业正在开发的治疗药

创伤后压力症候群(PTSD):大学/研究机关研究中的治疗药

创伤后压力症候群(PTSD):开发中产品的概要

  • 后期阶段的产品
  • 临床实验阶段的产品
  • 初期阶段的产品
  • 未确认阶段的产品

创伤后压力症候群(PTSD):开发中的产品的一览(各企业)

创伤后压力症候群(PTSD):研究中的产品的一览(大学/研究机关别)

创伤后压力症候群(PTSD)的开发企业

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Azevan Pharmaceuticals, Inc.
  • 分析的背景 Pharmaceutical Partners, Inc.
  • Eli Lilly and Company
  • HolsboerMaschmeyer NeuroChemie GmbH
  • Humanetics Corporation
  • Intra-Cellular Therapies, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Marinus Pharmaceuticals, Inc.
  • Neuralstem, Inc.
  • NeuroNascent, Inc.
  • Omeros Corporation
  • 大冢集团
  • Polleo Pharma Limited
  • Synchroneuron Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Turing Pharmaceuticals AG
  • Vanda Pharmaceuticals Inc.

创伤后压力症候群(PTSD):治疗药的评估

  • 单剂产品
  • 标的别
  • 各作用机制
  • 各投药法
  • 各分子类型

药物简介

  • acamprosate calcium SR
    • 产品概要
    • 功能机制
    • 研究开发(R&D)的发展情形
  • ADX-71743
  • AM-3506
  • brexpiprazole
  • CPP-115
  • Drug for Post-Traumatic Stress Disorders
  • Drugs to Inhibit FAAH for CNS Disorders
  • Drugs to Modulate NPSR for Anxiety Disorder
  • ganaxolone
  • HL-9001
  • IC-87201
  • iloperidone
  • INV-170
  • ITI-007
  • ketamine hydrochloride
  • NNI-351
  • NSI-189
  • Rycal
  • S-107
  • Small Molecule to Target GPR151 for CNS Diseases
  • Small Molecule to Target GPR83 for CNS and Immunological Disorders
  • Small Molecules for Post-Traumatic Stress Disorder
  • Small Molecules for Post-Traumatic Stress Disorder
  • Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders
  • Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders
  • Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder
  • Small Molecules to Antagonize TLR-4 for CNS Disorders
  • SRX-246
  • TNX-102
  • Vaccine for CNS Disorders
  • vigabatrin
  • ZL-006

创伤后压力症候群(PTSD):开发中产品的最新趋势

创伤后压力症候群(PTSD):开发暂停的产品

创伤后压力症候群(PTSD):开发中止的产品

创伤后压力症候群(PTSD)相关产品的开发里程碑

  • 值得注意的最新趋势·新闻稿

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11038IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 4, 19, 6 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Post-Traumatic Stress Disorder (PTSD) - Overview
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
  • Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
  • Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
  • Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Anagin Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Armgo Pharma Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Artelo Biosciences Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top